Forest Ends Daiichi Azor Deal To Focus On Its Own Products
This article was originally published in PharmAsia News
Executive Summary
Forest Laboratories regained the equivalent of 500 sales reps by terminating a three-year co-promotion deal with Daiichi Sankyo for the fixed-dose antihypertensive Azor, the company announced May 12.